- Home
- ATAI vs RCS Comparison
ATAI vs RCS Comparison
Compare ATAI & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATAI | RCS |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 269.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATAI | RCS |
|---|---|---|
| Price | $3.55 | $5.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $15.57 | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 140.6K |
| Earning Date | 03-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.12% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $308,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $5.24 |
| 52 Week High | $6.73 | $8.00 |
Technical Indicators
Market Signals| Indicator | ATAI | RCS |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 37.58 |
| Support Level | $3.48 | N/A |
| Resistance Level | $4.30 | $5.98 |
| Average True Range (ATR) | 0.21 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 27.41 | 20.83 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.